5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

Rachita Dhurat; Aseem Sharma; Lidia Rudnicka; George Kroumpouzos; Martin Kassir; Hassan Galadari; Uwe Wollina; Torello Lotti; Masa Golubovic; Iva Binic; Stephan Grabbe; Mohamad Goldust

doi:10.1111/dth.13379

5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

Rachita Dhurat, Aseem Sharma, Lidia Rudnicka, George Kroumpouzos, Martin Kassir, Hassan Galadari, Uwe Wollina, Torello Lotti, Masa Golubovic, Iva Binic, Stephan Grabbe, Mohamad Goldust

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

Abstract

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

Original language	English
Article number	e13379
Journal	Dermatologic Therapy
Volume	33
Issue number	3
DOIs	https://doi.org/10.1111/dth.13379
Publication status	Published - May 1 2020

Keywords

5-alpha reductase inhibitors
androgenetic alopecia
dutasteride
finasteride

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/dth.13379

Cite this

@article{7d95e249e6c54bdf8ddc0d46e22034a4,

title = "5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety",

abstract = "Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.",

keywords = "5-alpha reductase inhibitors, androgenetic alopecia, dutasteride, finasteride",

author = "Rachita Dhurat and Aseem Sharma and Lidia Rudnicka and George Kroumpouzos and Martin Kassir and Hassan Galadari and Uwe Wollina and Torello Lotti and Masa Golubovic and Iva Binic and Stephan Grabbe and Mohamad Goldust",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC.",

year = "2020",

month = may,

day = "1",

doi = "10.1111/dth.13379",

language = "English",

volume = "33",

journal = "Dermatologic Therapy",

issn = "1396-0296",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - 5-Alpha reductase inhibitors in androgenetic alopecia

T2 - Shifting paradigms, current concepts, comparative efficacy, and safety

AU - Dhurat, Rachita

AU - Sharma, Aseem

AU - Rudnicka, Lidia

AU - Kroumpouzos, George

AU - Kassir, Martin

AU - Galadari, Hassan

AU - Wollina, Uwe

AU - Lotti, Torello

AU - Golubovic, Masa

AU - Binic, Iva

AU - Grabbe, Stephan

AU - Goldust, Mohamad

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

AB - Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

KW - 5-alpha reductase inhibitors

KW - androgenetic alopecia

KW - dutasteride

KW - finasteride

UR - http://www.scopus.com/inward/record.url?scp=85083803337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083803337&partnerID=8YFLogxK

U2 - 10.1111/dth.13379

DO - 10.1111/dth.13379

M3 - Review article

C2 - 32279398

AN - SCOPUS:85083803337

SN - 1396-0296

VL - 33

JO - Dermatologic Therapy

JF - Dermatologic Therapy

IS - 3

M1 - e13379

ER -

5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this